Literature DB >> 1404367

Loop mutations can cause a substantial conformational change in the carboxy terminus of the ferritin protein.

R Jappelli1, A Luzzago, P Tataseo, I Pernice, G Cesareni.   

Abstract

Although some protein folding theories sustain that the peptides (loops) that connect elements of more compact secondary structure may be important in the folding process, most of the data accumulated until now seems to contradict this notion. To approach this problem we have isolated and characterized a number of mutants in which the amino acid sequence of the peptide that connects helix D and helix E in the H-chain of human ferritin has been randomized. Our results indicate that, though no single loop residue is absolutely required for ferritin to attain the native conformation, most of the mutants that we have obtained by random regional mutagenesis, affect its folding/assembly process. This conclusion was reached utilizing a sensitive test that associates the color formed by a colony synthesizing a hybrid ferritin-beta-galactosidase protein to the ability of the ferritin domain to fold and assemble as the native protein. The characterization of the folding/assembly properties of our collection of mutants and the comparison of the mutant loop sequences, have allowed us to draw the following conclusions. Mutants that have positively charged residues at position 159, 160 or 161 fail to assemble into the native protein shell and form an insoluble aggregate. Interestingly some loop amino acid sequences cause the E-helix to reverse direction and to expose its COOH group, normally hidden inside the protein cavity, to the solvent. The propensity of a given ferritin mutant to fold into this "non-native" conformation can be attenuated by the introduction of Gly at position 159 and 164, as in the natural ferritin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1404367     DOI: 10.1016/0022-2836(92)90905-y

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  6 in total

1.  Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires.

Authors:  N Dimasi; F Martin; C Volpari; M Brunetti; G Biasiol; S Altamura; R Cortese; R De Francesco; C Steinkühler; M Sollazzo
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Effects of modifications near the 2-, 3- and 4-fold symmetry axes on human ferritin renaturation.

Authors:  P Santambrogio; P Pinto; S Levi; A Cozzi; E Rovida; A Albertini; P Artymiuk; P M Harrison; P Arosio
Journal:  Biochem J       Date:  1997-03-01       Impact factor: 3.857

3.  Mutant L-chain ferritins that cause neuroferritinopathy alter ferritin functionality and iron permeability.

Authors:  Justin R McNally; Matthew R Mehlenbacher; Sara Luscieti; Gideon L Smith; Aliaksandra A Reutovich; Poli Maura; Paolo Arosio; Fadi Bou-Abdallah
Journal:  Metallomics       Date:  2019-10-16       Impact factor: 4.526

4.  Mutant ferritin L-chains that cause neurodegeneration act in a dominant-negative manner to reduce ferritin iron incorporation.

Authors:  Sara Luscieti; Paolo Santambrogio; Béatrice Langlois d'Estaintot; Thierry Granier; Anna Cozzi; Maura Poli; Bernard Gallois; Dario Finazzi; Angela Cattaneo; Sonia Levi; Paolo Arosio
Journal:  J Biol Chem       Date:  2010-02-16       Impact factor: 5.157

5.  Directed plant cell-wall accumulation of iron: embedding co-catalyst for efficient biomass conversion.

Authors:  Chien-Yuan Lin; Joseph E Jakes; Bryon S Donohoe; Peter N Ciesielski; Haibing Yang; Sophie-Charlotte Gleber; Stefan Vogt; Shi-You Ding; Wendy A Peer; Angus S Murphy; Maureen C McCann; Michael E Himmel; Melvin P Tucker; Hui Wei
Journal:  Biotechnol Biofuels       Date:  2016-10-21       Impact factor: 6.040

6.  Iron-mediated aggregation and a localized structural change characterize ferritin from a mutant light chain polypeptide that causes neurodegeneration.

Authors:  Martin A Baraibar; Ana G Barbeito; Barry B Muhoberac; Ruben Vidal
Journal:  J Biol Chem       Date:  2008-08-28       Impact factor: 5.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.